AMLEXANOX
LOE Approachingamlexanox
NDATOPICALPATCH
Approved
Sep 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Amlexanox is a topical patch formulation approved in 2004 for localized treatment of oral lesions and aphthous ulcers. The drug works through anti-inflammatory and immunomodulatory mechanisms to reduce ulcer pain and promote healing. It is a small molecule therapeutic delivered via transmucosal patch technology.
LOE Approaching
Product is in mature/declining phase with limited commercial expansion opportunities; teams are typically lean and focused on lifecycle management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on amlexanox offers limited career momentum given its LOE-approaching status and zero linked job openings. This is a maintenance/legacy product role suited for professionals focused on lifecycle management rather than innovation or growth.
Brand ManagerSales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.